The global Peptide Therapeutics Market is valued at USD 117.26 Billion in 2022 and is projected to reach a value of USD 367 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 10.95% between 2023 and 2030.

Premium Insights

The market for Peptide Therapeutics has been driven by the rising incidence of chronic illnesses and the expanding need for individualized and focused treatments. Pharmaceutical Research and Manufacturers of America (PhRMA) reports that peptide-based medications have demonstrated great promise in the treatment of numerous illnesses, including diabetes, cardiovascular disease, and cancer. Peptide synthesis technology developments, increased R&D spending, and an aging population in need of novel treatment alternatives are some of the causes contributing to this expansion. Further driving market expansion are the move towards biologics and the growing popularity of peptide-based medications because of their high selectivity and low adverse effects. The Peptide Therapeutics market is anticipated to maintain its speed in the next years due to the combined effects of academic research, pharmaceutical alliances, and regulatory assistance.

• The increasing prevalence of chronic diseases an spurring demand for targeted and personalized treatment are major drivers for the {keyword}} market.
• The branded peptides segment will continue to assert its dominance by type, capturing the largest market share globally throughout the forecast period 2023 to 2030.
• In 2022, North America exhibited its market prowess, achieving the highest revenue share of over 40.9%.
• The Asia Pacific region is poised for remarkable growth, displaying a noteworthy Compound Annual Growth Rate (CAGR) between 2023 and 2030.

Top Market Trends

1. The incorporation of customized medicine approaches is a notable and persistent trend in the peptide therapies market. Personalized peptide-based therapy is becoming more and more important as genomes and biomarker research continue to progress. By choosing the best peptides based on a patients genetic profile and disease factors, this movement seeks to maximize therapeutic outcomes. A new era of precision medicine in healthcare is being ushered in by pharmaceutical corporations' increased investment in research and development to build individualized peptide medicines.
2. The ongoing development of peptide drug pipelines across a range of therapeutic domains is another noteworthy trend. Innovative peptide-based medications are being developed by biotechnology and pharmaceutical companies to diversify their portfolios over a broad spectrum of indications aggressively. Peptides are being investigated as possible possibilities for anything from cancer immunotherapy to neurological diseases. The increasing success rates in clinical trials and our expanding understanding of peptide pharmacology are driving this trend, which suggests that peptide therapies have a bright future in meeting unmet medical needs.

Economic Insights

Like many other industries, the Peptide Therapeutics market was affected by COVID-19 in both positive and negative ways. At first, the pandemic caused delays in research and development by interfering with clinical studies and supply chains. Nevertheless, the market proved resilient, as seen by the sharp rise in demand for antiviral medications and vaccines based on peptides. The World Health Organization (WHO) reports that several COVID-19 vaccines based on peptides have begun clinical testing, demonstrating the versatility of peptide technology in reacting to new health emergencies. Additionally, the pandemic highlighted the value of novel treatments, which encouraged investments in the development of peptide drugs. The market had a noteworthy growth trajectory despite obstacles. This demonstrates the industrys tenacity and capacity to flourish under trying conditions while advancing the state of healthcare solutions.

Market Segmentation

Peptide Therapeutics {{Segmentation_Ext}}

Based on Type

Branded Peptides to Dominate Valuable Revenue owing to Increased Effectiveness

Branded peptides dominate the market for peptide therapies. Their well-established reputation for effectiveness, safety, and quality is the main factor contributing to their domination. Reputable pharmaceutical businesses create and sell branded peptides, frequently following protracted clinical trials and investigational studies. Because of the increased trust that this fosters between patients and healthcare providers, branded peptides are the recommended treatment option for a variety of illnesses. Furthermore, complete support services, such as patient education and assistance programs, are often included with branded peptides, which further increases their market visibility. While generic peptides can be less expensive, they might not necessarily function as well clinically or have the same degree of confidence attached to them. For this reason, many patients and healthcare professionals who are looking for safe and efficient therapies prefer branded peptides.

Based on Application

Cancer-based Application to Regain the Most Value Owing to Increasing Prevalence of Cancer

In 2022, within the market for peptide therapies, cancer has the second-largest share after metabolic category. The complexity of cancer and the adaptability of peptides in addressing different facets of the illness are the main causes of its predominance. Because peptide-based medications offer a high selectivity for identifying cancer cells while avoiding healthy ones, they have shown remarkable promise in the treatment of cancer. It is noteworthy that many peptide medications are made to block particular oncogenic pathways or impede the growth of tumours, which has attracted the interest of researchers and pharmaceutical businesses alike. This fields substantial ongoing research and development activities have produced a strong pipeline of peptide-based cancer medicines, solidifying its position as the industry leader.

Based on the Route of Administration

Oral Deliveries to Witness Significatn Growth Owing to Increasing Preference by Patients and Healthcare Professionals

In 2022, the oral delivery category to witness substantial share in the global market. This supremacy is the result of numerous important causes. First off, oral administration is a convenient and non-invasive way to distribute drugs that both patients and healthcare professional’s favor. Second, it promotes more treatment adherence by removing the need for injections and other invasive procedures, which improves patient compliance. Oral formulations are also economically appealing because they frequently have a better cost-effectiveness profile than parenteral methods. Developments in formulation technology have also increased the stability and bioavailability of peptide medications taken orally, which has increased their marketability and usability even more.

Based on Manufacturers Type

Outsourced Manufacturing to Witness Fastest Growth Owing to Increased Dependency and Widening Demand

In 2022, outsourced manufacturing had a substantial share and is estimated to witness fastest growth in the coming years. This is mainly because pharmaceutical companies can benefit from outsourcing in several ways. By doing so, they can make use of the peptide synthesis and production experience of specialist contract manufacturing organizations (CMOs), which frequently leads to improved product quality and cost-effectiveness. Additionally, outsourcing frees up cash for large upfront infrastructure and equipment purchases, allowing businesses to spend their resources more wisely. In addition, it offers flexibility because CMOs can swiftly adjust production capacity in response to changes in demand, lowering the risks involved with making a large commitment to in-house production. In the competitive Peptide Therapeutics market, outsourcing has emerged as the go-to option for many pharmaceutical companies looking to optimize their operations and boost productivity.

Based on Synthesis Technology

SPPS Technology to Overtake as the Dominant Provider Owing to a Greater Efficiency and Control

In 2022, in the market for peptide therapies, solid phase peptide synthesis, or SPPS, had a substantial share. Its popularity is explained by several significant benefits that it provides. Peptide synthesis can be done with great efficiency and control using SPPS, which makes it possible to assemble complicated peptide sequences precisely. Higher purity and yield are achieved through the synthesis of longer peptides with fewer side reactions, made possible by the solid-phase support, which also makes purification easier. Furthermore, SPPS is scalable and affordable for large-scale production because it can be automated. Although hybrid technologies and liquid phase peptide synthesis (LPPS) offer advantages, SPPS is the method of choice for most peptide medication production and development activities due to its efficiency, dependability, and broad use.

Based on the Distribution Channel

Retail Pharmacies to Witness Fastest Growth Owing to Increasing Ease of Use and Accessibility to Patients

In 2022, the retail pharmacies category to witness fastest growth. The main reason for their prevalence is the ease of use and accessibility they provide to patients. It is easier for people to obtain their prescribed peptide-based drugs because retail pharmacies are frequently situated near residential areas. Pharmacists can help patients by providing advice and support, which builds familiarity and trust. Additionally, retail pharmacies usually take a variety of insurance policies, which lowers the cost of prescription drugs for patients—including peptide therapies. Retail pharmacies continue to rule the market despite the growing popularity of internet pharmacies because of their established presence and solid patient-provider relationships, which guarantee quick and dependable access to peptide-based medicines.

Based on Region

North American Peptide Therapeutics Market to Accommodate a Wider Market Share Owing to Widening Pharmaceutical Sector

North America dominates the Peptide Therapeutics industry for several important reasons. First off, it has a thriving pharmaceutical sector that prioritizes research and development, which has resulted in the identification and release of numerous peptide-based medications. Second, the area gains from a developed healthcare system that comprises a robust hospital and research institution network. The market is expanding due in part to favorable regulatory frameworks and increased healthcare spending. North Americas supremacy is further cemented by the existence of significant pharmaceutical corporations and a high level of knowledge among healthcare professionals.

The Asia Pacific regions developing healthcare sector, rising R&D spending, and expanding patient base are the main reasons behind the markets rapid expansion in the peptide therapies space. Peptide-based medications are among the novel therapeutics that are in higher demand due to the increasing awareness of healthcare issues and disposable cash. Furthermore, the Asia Pacific area has drawn interest from all over the world as a hub for pharmaceutical industry clinical trials and partnerships. It is a significant rising participant in the worldwide Peptide Therapeutics market, and its expansion is further bolstered by government efforts targeted at promoting innovation and expanding healthcare accessibility.

Competitive Landscape

The market for peptide treatments is very competitive, with both well-established pharmaceutical behemoths and cutting-edge biotechnology startups. Industry leaders Novartis, Eli Lilly, and Roche control a large portion of the peptide-based medication industry with substantial R&D spending and a diversified array of products. Smaller biotech companies like AstraZeneca and Amgen, however, are becoming more well-known because of innovative treatments. Peptide synthesis-focused contract manufacturing organizations (CMOs), such as Polypeptide Group and Bachem, offer crucial support services. Due to constant R&D, strategic alliances, product pipeline and market expansion initiatives, this competitive market encourages rivalry.

The key players in the global Peptide Therapeutics market include - International Paper Company, DS Smith Plc, Smurfit Kappa Group PLC, Sonoco Products Company, Menasha Packaging Company LLC., Georgia-Pacific LLC, WestRock Company, Pratt Industries Inc., Marketing Alliance Group, FFR Merchandising Company among others.

Recent Market Developments

• April 2023: The somapacitan-beco injectable was given expanded FDA approval for use in children with GHD who are 2.5 years of age or older.
• March 2023: To make the cost of out-of-pocket prescriptions more manageable, Sanofi reduced the price of its popular insulin Lantus by 78%, with a cap of $35 USD for all patients with commercial insurance.
• November 2022: Enterome used its bacterial mimicking drug discovery platform to create one of the first-in-class immunomodulatory medications. To treat patients with initial progression or recurrence of glioblastoma, Enterome published the safety, immunogenicity, and effectiveness findings of their Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (ROSALIE trial).
• September 2022: Albumedix Ltd. was acquired by the life science business Sartorius through its French-listed unit Sartorius StedimBiotech. One of the major participants in the field of recombinant albumin-based solutions is Albumedix.

Segmentation of the Global Peptide Therapeutics Market